Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer

This article was originally published on Nasdaq

Exelixis, Inc. EXEL announced that it has initiated the phase III STELLAR-303 study that is evaluating its next-generation tyrosine kinase inhibitor, XL092, in combination with atezolizumab for treating patients with metastatic colorectal cancer (“CRC”).